1 / 11

Specific Aims

Stable Isotope-Resolved Metabolomics (SIRM) Core Teresa W-M. Fan, Richard M. Higashi, Hunter N.B. Moseley, Michael H. Nantz. Specific Aims.

kathyv
Download Presentation

Specific Aims

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stable Isotope-Resolved Metabolomics (SIRM) CoreTeresa W-M. Fan, Richard M. Higashi, Hunter N.B. Moseley, Michael H. Nantz

  2. Specific Aims Specific Aim 1.To implement and further develop high-information-throughput (HIT) profiling of stable isotope-labeling patterns in metabolites using FT-ICR-MS and NMR- the SIRM approach Specific Aim 2. To build atom-resolved human metabolic network and chemical moiety-based non-steady state metabolic flux modeling capability. Specific Aim 3. To establish the mechanisms of metabolic changes and regulation associated with concentration-based biomarkers of drug response in cardiovascular and neuropsychiatric diseases discerned from human subject studies.

  3. General Approach • Stable Isotope-Resolved Metabolomics (SIRM) • Propagate cells in culture in the presence of 13C6-glucose, 13C5/15N2Gln or other labeled metabolic precursors specific for a particular network project and measure the response to perturbations such as drugs. • 13C/15N2 isotopomer/isotopologue analysis of intracellular and extracellular metabolites using NMR & MS with minimal sample preparation. • Use atom-resolved biochemical network modeling to reconstruct the relevant metabolic network segments and how they are impacted by the treatment • Generate testable hypotheses about the effects of the therapeutic at the protein and gene levels that can be mechanistically linked to the functional data in the collaborating projects

  4. Example: 13C-labeling patterns : Krebs cycle Two turns of the cycle (source = 13C6-glucose)

  5. SIRM: Mass spectrometry FT-ICR-MS analysis of intact lipids in mammalian cell extracts. The simultaneous attainment of accurate mass and ultra high-resolution by FT-ICR-MS enables thousands of ions from > 250 lipids and their 13C isotopologues to be resolved and assigned. Illustrated is the identification of phosphadidylinositol (PI) with C18:0 and C20:4 acyl chains based on the molecular formulae of source (M) and acyl chain fragment ions (from MS/MS data) deduced from the corresponding accurate masses. Also shown is the resolution of a series of 13C isotopologue ions (M+3, M+5, M+7, etc.) representing multiple 13C labels in PI. Consequently, the suppression of de novo fatty acid biosynthesis from 13C6-Glc by selenite treatment is clearly demonstrated.

  6. Chemical biology for targeting compound classes and enhancing MS sensitivity Aminooxy-charged nanoparticles for oxime formation with carbonylated metabolites (O=C-R). Adds a permanent positive charge, hereby enhancing positive mode (nano)ES-MS sensitivity

  7. SIRM: NMR 13C6Glclabels Lactate, Ala, and all isotopomers of Glu/GSH in cancer cells (left panel)- complete turn of TCA. Isotopomer patterns describe the 13C atom incorporation at specific positions (right panel), that can be quantified in quantified in TOCSY. Such data are critical for network modeling. Lane, A.N. & Fan, T. W-M. (2007)

  8. Modeling: metabolic modules Biosynthesis of UDP-GlcNAc Chemical substructure model representing the possible number of 13C incorporation from 13C6-Glc tracer into UDP-GlcNAc,and biosynthetic pathway from 13C6-Glc. Uracil derives from glycolysis, the citric acid cycle (CAC) and pyrimidine biosynthesis. Ribose is made in the pentose phosphate pathway (PPP). The Acetyl moiety is derived from glycolysis and PDH Right: 13C isotopologues of UDPGlcNAc. The program GAIMS determines the populations of the individual species from FT-ICR-MS data after stripping natural abundance (Moseley (2010)).

  9. Network Applications • Stable isotope-labeled tracers and isotopomer/isotopologueprofiling are indispensible for tracing metabolic networks at the atomic level. These will be applied to network projects including: • 1. Functional consequences of gene polymorphism associated with differential anti-depression drug response in human subjects (PI Dr. Weinshilboum). • 2. Altered biochemical pathways and differential SSRI response mechanism in depression rodent model (PI Dr. Sanacora). • 3. Altered cellular pathways and regulation of lipid metabolism in relation to statin efficacy and gene polymorphism (PI Dr. Krause).

  10. Making Sense of the data: Metabolic Flux Modeling and Databases • Biochemical understanding of the pathology needs close collaborations with the projects and other cores for: • Optimal experimental design • Database tools such as HumanCyc, atom-resolved network modeling (http://www.metabolome.jp/software; http://humancyc.org/; http://www.hmdb.ca/) • Flux modeling • The core will work closely with the • Informatics core (S. Subramanian, B. Palsson), • Analytical core (O. Fiehn, T. Hankemeier) • Database core (S. Subramanian, R. Pietrobon, D. Wishart)

  11. Bibliography Arita, M. (2003) In silico atomic tracing by substrate-product relationships in Escherichia coli intermediary metabolism.Genome Research, 13: 2455-2466. Fan, T. W-M., Lane, A.N. & Higashi, R.M., (2004) The Promise of Metabolomics in Cancer Molecular Therapeutics. Current Opin. Molec. Ther. 6:584-592 Fan, T. W-M., Bandura, L.L., Lane, A.N. & Higashi, R.M., (2006) “ Integrating Genomics and Metabolomics for Probing Se Anticancer Mechanisms” Drug Metabolism Reviews 38, 1-25 Fan, T.W-M. & Lane, A.N. (2008) Structure-based profiling of Metabolites and Isotopomers by NMR, Prog. NMR Spectrosc. 52: 69-117 Fan, T.W-M., Lane, A.N., Higashi, R.M., Farag, M.A., Gao, H., Bousamra, M. & Miller, D.M. (2009) Altered Regulation of Metabolic Pathways in Human Lung Cancer Discerned by 13C Stable Isotope-Resolved Metabolomics (SIRM). Molecular Cancer. 8:41 Fan, T. W-M. Yuan, P., Lane, A.N., Higashi, R.M. Wang, Y., Hamidi, A., Zhou, R., Xavier Guitart-Navarro, X., Chen, G., Manji, H.K., Kaddurah-Daouk, R.(2010)Stable Isotope Resolved Metabolomic Analysis of Lithium Effects on Glial-Neuronal Interactions. Metabolomics 6, 165 – 179. Lane, A.N. & Fan, T. W-M. (2007) Determination of positional isotopomers in metabolites. Metabolomics 3: 79-86 Lane, A.N., Fan, T-W-M. & Higashi, R.M. (2008) “Isotopomer-based metabolomic analysis by NMR and mass spectrometry". Methods in Cell Biology, 84: 541-588. Lane, A.N., Fan, T. W-M., Xie, X. Moseley, H.N. & Higashi, R.M. (2009) Stable isotope analysis of lipid biosynthesis by high resolution mass spectrometry and NMR. Anal. Chim. Acta. 651: 201-208 Moseley, H.N.B. (2010) Correcting for the effects of natural abundance in stable isotope resolved metabolomics experiments involving ultra-high resolution mass spectrometry.BMC Bioinformatics 11:139 Selivanov, V.A., et al., (2006). Software for dynamic analysis of tracer-based metabolomic data: estimation of metabolic fluxes and their statistical analysis Bioinformatics 22: 2806-2812. Sumner, L.W., Amberg, A., Barrett, D., Beger, R., Beale, M.H., Daykin, C. Fan, T. W-M., Fiehn, O., Goodacre, R., Griffin, J.L., Hardy, N., Higashi, R.M., Kopka, J., Lindon, J.C., Lane, A.N., Marriott, P., Nicholls, A.W., Reily, M.D., Viant, M. (2007) Proposed Minimum Reporting Standards for Chemical Analysis. Metabolomics. 3, 211-221

More Related